Case report

Vaginal sarcoidosis without other organ involvement in a patient with a history of endometrial cancer: A case report

Knisely A.T. a, Girton M.R. b, Hintz H.C. a, Modesitt S.C. c,⁎

a University of Virginia Health System, Charlottesville, VA, United States
b Department of Pathology, University of Virginia School of Medicine, Charlottesville, VA, United States
c Gynecologic Oncology Division, Department of Obstetrics and Gynecology, University of Virginia School of Medicine, Charlottesville, VA, United States

ARTICLE INFO

Keywords:
Vaginal sarcoidosis
Endometrial cancer
Granulomatous inflammation

1. Introduction

Granulomatous inflammation is a histologic pattern containing histiocytes, or activated macrophages, that can be seen in tissues following cell injury. Its differential diagnosis is broad and includes infectious, autoimmune, toxic, allergic, and neoplastic conditions (Shah et al., 2017). Sarcoidosis is a systemic granulomatous disease that can affect any organ. Pulmonary and hilar lymph node involvement is by far the most common manifestation, present in 90% of cases, but other sites, including the skin, eye, liver, heart, and peripheral lymph nodes, may also be involved in 10–30% of cases (Judson, 2015). The female genital tract is the most rarely involved at < 1% of cases (Rosenfeld et al., 1989). The first vulvar sarcoidosis case was reported in 1985 (Tatnall et al., 1985), and most subsequent case reports have described uterine or vulvar involvement. To date, only a handful of vaginal sarcoidosis case reports have been published, primarily in association with other organ involvement (Allen and Judson, 2010; Xu et al., 2012; Schol et al., 2013; Sahin et al., 2016). A confounding factor in this particular case, which differentiates it from that which has been previously reported (Bakali et al., 2012), is that the patient has a history of endometrial cancer.

2. Case report

A 60-year-old woman presented to the gynecologic oncology clinic with a one-month history of markedly increased mucous vaginal discharge. She had a history of stage IIIA grade 1 endometrial adenocarcinoma status post TAH/BSO, omentectomy, and bilateral pelvic and para-aortic lymph node dissection followed by 6 cycles of chemotherapy (Carbo/Taxol) and had been in remission for the past eight years. She had a normal pelvic exam two months prior to this presentation. Her past medical and surgical histories are otherwise unremarkable. Physical exam demonstrated copious brown/mucus discharge and vaginal circumferential thickening with a more pronounced 2 × 3 cm area of thickening in the rectovaginal septum. Given concern for cancer recurrence, the patient underwent a vaginal biopsy and pelvic MRI. CA-125 level, which was elevated at 182 U/mL at time of cancer diagnosis, was normal at 10 U/mL.

The biopsy specimen exhibited non-necrotizing granulomatous inflammation and neither acid fast bacilli (AFB) nor fungal organisms were identified on AFB and Gomori methenamine silver stains, respectively (Fig. 1). In addition, the patient had no history of fever, cough, night sweats, new exposures, or GI symptoms and she had a normal colonoscopy one year prior to initial presentation. Pelvic MRI showed concentric thickening of the anterior and posterior vaginal walls but no discrete mass effect (Fig. 2A) and this was not consistent with a cancer recurrence. Dermatology and rheumatology were also consulted to help guide further work up and a chest radiograph, anti-nuclear antibody (ANA), rapid plasma reagin (RPR), C-reactive protein (CRP), and Prometheus inflammatory bowel disease (IBD) panel were all negative/normal.

After initial workup was negative for other etiologies, the lesion was treated as an inflammatory process with a methylprednisolone taper, which resulted in moderate symptomatic improvement, especially with the discharge. However, her symptoms returned after completion of the steroid taper and she was therefore started on dexamethasone 4 mg BID, weaned to 2 mg daily, along with vaginal triamcinolone. This medication regimen resulted in marked improvement on physical exam.
and resumption of sexual activity. Due to atrophy, vaginal estrogen was added and the patient was eventually completely weaned off oral steroids four months after her initial presentation. She has since remained stable with respect to symptoms and physical exam on QOD vaginal steroids alternating with estrogen. On her most recent follow up, the discharge had improved and physical exam showed near resolution of rectovaginal thickening and stable anterior vaginal wall thickening. Repeat MRI showed interval near complete resolution of previously seen enhancement abnormalities within the vagina (Fig. 2B).

3. Discussion

In this case of a patient with a history of endometrial cancer presenting with a new vaginal mass shown to contain granulomatous inflammation on pathologic review, there are many etiologies to consider. Although vaginal sarcoidosis is our leading diagnosis in this case, the pathologic findings are not specific and the differential diagnosis for non-necrotizing granulomatous inflammation includes a number of other possibilities, including infections, other inflammatory/autoimmune processes, toxins, drug reactions, and neoplasms (“sarcoid-like” reactions). Refer to Table 1 for a list of specific etiologies within each category.

Some of the more common infectious etiologies to consider include coccidiomycosis (Chen et al., 1993), lymphogranuloma inguinale (Sami and Baloch, 2005), and tuberculosis (Ferrara et al., 1999). These are less likely in our case, given the lack of bacteria and fungal organisms with appropriate staining, and there were no findings on chest radiograph to support existence of a tuberculosis or fungal infection. Additionally, RPR was negative, ruling out syphilis. Of the inflammatory/autoimmune causes of non-necrotizing granulomas, Crohn’s disease and lupus are the two of the more common ones after sarcoidosis. Crohn’s disease was excluded given her lack of suggestive symptoms, a normal colonoscopy one year prior, normal CRP (< 0.1 mg/dL), and a negative IBD panel. Lupus was essentially ruled out, as the patient’s ANA, a very sensitive marker for the disease, was normal. To address toxic and drug exposures, we relied on history from the patient; she denied any new environmental exposures and any new products or medications, specifically antibiotics and methotrexate. A normal blood count and lack of any other systemic symptoms put hematologic malignancies low on our differential diagnosis. Given her negative workup, many of the
alternative diagnoses were excluded and vaginal sarcoidosis emerged as the most likely diagnosis. Despite the fact that vaginal involvement is a rare manifestation of this multisystem disease, there are reports in the literature and this diagnosis is one of exclusion and is supported by the pathologic findings in this case. There are some serum markers that may be elevated in cases of sarcoidosis, including calcium, angiotensin converting enzyme, serum amyloid-A, soluble interleukin-2 receptor, lysozyme, and glycoprotein KL-6. In our patient we looked at serum calcium only. The fact that calcium was normal (9.2 mg/dL) and that other markers were not tested does not rule out sarcoidosis, as these are non-specific and are classically associated with pulmonary sarcoidosis (Miyoshi et al., 2010); our patient does not have evidence of systemic disease, specifically pulmonary involvement.

An additional interesting aspect of this case is the patient's history of endometrial cancer and associated treatment. Specifically, given this patient's history of a hysterectomy, we cannot rule this out as a chronic reactive response to prior surgery or suture material (Bardales et al., 1995). However, the patient is more than eight years out from surgery and the thickening did not appear at the vaginal cuff, so the likelihood of this as the cause for her physical exam findings and symptoms is thought to be unlikely. Additionally, no foreign body material was identified on physical exam or imaging.

This case report demonstrates that, although rare, sarcoidosis as well as other granulomatous processes should be considered when evaluating a patient with thickening of vaginal tissues or a vaginal mass, and prompt histological assessment is critical to diagnosis and treatment. There are reports of treatment with oral steroids, topical steroids, and methotrexate (Sahin et al., 2016). In our patient, oral steroids were required initially but ultimately she could be managed on topical corticosteroids and estrogen. It is also important to consult subspecialists to ensure thorough evaluation for other possible etiologies as well as obtain expert advice on appropriate treatment regimens and follow up.

Conflicts of interest

The authors report no conflicts of interest.

References

Allen, S.L., Judson, M.A., 2010. Vaginal involvement in a patient with sarcoidosis. Chest 137 (2), 455–456.
Bakali, E., et al., 2012. Solitary vaginal sarcoidosis without other manifestations of systemic disease. J. Obstet. Gynaecol. 32 (8), 814–816.
Bardales, R.H., et al., 1995. Cryptococcal infection of the vagina. Obstet. Gynecol. 81 (5), 867–869.
Ferrara, G., et al., 1999. Nested polymerase chain reaction on vaginal smears of tuberculous cervicitis: a case report. Acta Cytol. 43 (2), 308–312.
Judson, M.A., 2015. The clinical features of sarcoidosis: a comprehensive review. Clinic. Rev. Allerg. Immunol. 49, 63–78.
Miyoshi, S., et al., 2010. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 137 (6), 1381–1397.
Rosenfeld, S.I., et al., 1989. Sarcoidosis of the female genital tract: a case presentation and survey of the world literature. Int. J. Gynecol. Obstet. 28, 373–380.
Sahin, C.K., et al., 1993. Cryptococcal infection of the vagina. Obstet. Gynecol. 81 (5), 867–869.
Sami, S., Baloch, S.N., 2005. Vaginitis and sexually transmitted infections in a hospital based study. J. Pak. Med. Assoc. 55 (6), 242–244.
Schoi, P.B., et al., 2013. Vaginal sarcoidosis. J. Obstet. Gynaecol. 33 (4), 426.
Shah, K.K., et al., 2017. Histopathologic review of granulomatous inflammation. J. Clin. Tuberc. Other Mycobact. Dis. 7, 1–12.
Tatnall, F.M., et al., 1985. Sarcoidosis of the vulva. Clin. Exp. Dermatol. 10 (4), 384–385.
Xu, F., et al., 2012. Sarcoidosis: vaginal wall and vulvar involvement. Sarcoidosis Vasc. Diffuse Lung Dis. 29 (2), 151–154.